Alcobra Ltd. (NASDAQ:ADHD) shares traded down 1.9% during trading on Thursday . The company traded as low as $4.58 and last traded at $4.70, with a volume of 63,960 shares changing hands. The stock had previously closed at $4.79.

A number of research analysts have commented on the company. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating on the stock. Cantor Fitzgerald began coverage on Alcobra in a research report on Tuesday, June 7th. They set a “buy” rating and a $16.00 target price for the company. Roth Capital reiterated a “buy” rating and set a $12.00 target price on shares of Alcobra in a research report on Tuesday, June 21st. Finally, Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Thursday, April 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.63.

The firm has a 50 day moving average of $4.79 and a 200 day moving average of $4.74. The firm’s market capitalization is $127.34 million.

Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.04. Analysts predict that Alcobra Ltd. will post ($0.98) earnings per share for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.